In vivo tumor-suppressing and anti-angiogenic activities of a recombinant anti-CD3ε nanobody in breast cancer mice model.
Sign Up to like & getrecommendations! Published in 2019 at "Immunotherapy"
DOI: 10.2217/imt-2019-0068
Abstract: Aim: Achievements in cancer immunotherapy require augmentation of a host's anti-tumor immune response for anti-cancer modality. Materials & methods: Different concentrations of recombinant anti-CD3 nanobody were administered at predetermined time intervals during a 24-day treatment period… read more here.
Keywords: recombinant anti; nanobody; anti cd3; cancer ... See more keywords